Ravi Vij, MD, MBA, Washington University School of Medicine, Saint Louis, MO, outlines the final analysis of patient-reported outcomes data from ELOQUENT-2 study (NCT01239797) of elotuzumab plus lenalidomide/dexamethasone (Ld) in patients with relapsed/refractory (R/R) multiple myeloma (MM). This final analysis confirms that the efficacy benefits observed with addition of elotuzumab to Ld in patients with R/R MM were achieved without negatively affecting health-related quality of life compared with Ld. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
Speaker: Ravi Vij,Event: ASH 2019,Format: Interview,Subject: Multiple Myeloma,Field: Trial Updates,Field: Treatment,Trial: ELOQUENT-2,Medicines: Elotuzumab,Medicines: Lenalidomide,Medicines: Dexamethasone,Field: Immuno-Oncology,Medicines: Antibodies,NCT01239797,quality of life,HRQoL,patient-reported outcomes,
Ravi Vij, MD, MBA, Washington University School of Medicine, Saint Louis, MO, outlines the final analysis of patient-reported outcomes data from ELOQUENT-2 study (NCT01239797) of elotuzumab plus lenalidomide/dexamethasone (Ld) in patients with relapsed/refractory (R/R) multiple myeloma (MM). This final analysis confirms that the efficacy benefits observed with addition of elotuzumab to Ld in patients with R/R MM were achieved without negatively affecting health-related quality of life compared with Ld. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
0 Comments